Blocking of CD47 was performed with purified mouse anti-human CD47 mAb (αCD47-fuFc ... Developing tumor-specific IgG2 mAbs with apoptotic capacity presents a promising approach to enhance ...

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II ...

Matthew R. Levengood; Christopher M. Carosino; Xinqun Zhang; Sasha Lucas; David J. Ortiz; Lori Westendorf; Alice P. Chin; Arlan D. Martin; Abbie Wong; Shawna M ...

A preclinical study of HX009 last year indicated the bispecific antibody has a strong affinity toward binding to PD-1 but a weaker affinity to CD47. This characteristic allows better targeting to ...

Trending scientific news on hot topics and the latest discoveries in the world of science and medicine. Browse relevant news and current events from a wide variety of scientific categories.

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC. Syros Pharmaceuticals on Tuesday ...